Monograph Details
|
|
Immune System
> Immunomodulators
|
|
AZASAN |
| Manufacturer |
|
Salix Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immunosuppressant. |
| Generic Name |
|
Azathioprine 75mg, 100mg; scored tabs. |
| Indications |
|
Adjunct for the prevention of rejection in renal homotransplantation. |
| Children |
|
Not recommended. |
| Adults |
|
Start at time of transplant or 1–3 days prior; usually with IV formulation. Initially: 3–5 mg/kg daily. Maintenance: 1–3mg/kg daily. |
| Contraindications |
|
Pregnancy (Cat.D). |
| Precautions |
|
Be fully familiar with product's toxicity before use; consider discontinuing if severe toxicity occurs. Risk of myelotoxicity with low or absent thiopurine S-methyl transferase (TPMT) activity. Monitor blood. Impaired renal function. Nursing mothers: not recommended. |
| Interactions |
|
Reduce dose to ⅓ or ¼ with allopurinol. TPMT enzyme inhibition with aminosalicylates (eg, sulphasalazine, mesalazine, olsalazine). Leukopenia with co-trimoxazole. Anemia, leukopenia with ACE Inhibitors. May antagonize warfarin. |
| Adverse Reactions |
|
Severe leukopenia and/or thrombocytopenia, macrocytic anemia, pancytopenia, severe bone marrow suppression, GI disturbances, secondary infections, mutagenic and carcinogenic potential, hepatotoxicity, rash. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
